@article { author = {Mirtavoos-Mahyari, Hanifeh and Khosravi, Adnan and Esfahani-Monfared, Zahra}, title = {Human Epidermal Growth Factor Receptor 2 and Estrogen Receptor Status in Respect to Tumor Characteristics in NonMetastatic Breast Cancer}, journal = {TANAFFOS (Respiration)}, volume = {13}, number = {1}, pages = {26-34}, year = {2014}, publisher = {National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran}, issn = {1735-0344}, eissn = {2345-3729}, doi = {}, abstract = {Background: The expressions of estrogen receptor (ER) and cell surface receptor, Tyrosine Kinase Human Epidermal Growth Factor Receptor 2 (HER 2), have emerged as the most important molecular biomarkers determining the breast cancer prognosis. In this study, interactions between ER and HER2 were assessed to determine if they modulate tumor characteristics. Materials and Methods: Tissue samples from 120 patients with early stage breast cancer receiving adjuvant chemotherapy were reviewed to evaluate ER and HER2 status quantified by immunohistochemistry and fluorescence in situ hybridization, and the correlation of ER and HER2 with patient characteristics and tumor pathology was studied. Results: A total of 37(30.8%) and 80(66.6%) out of 120 samples were HER2 (3+ by immunohistochemistry or positive by fluorescent in situ hybridization) and ER positive (by immunohistochemistry), respectively. ER-negative tumors were significantly more likely to be HER-2 positive than were ER-positive tumors (21.25%; odds ratio, 0.270; 95% CI, 0.119 to 0.612; P=0.002). ER positivity was associated with}, keywords = {Breast cancer,Tumor,Estrogen receptor,Human Epidermal Growth Factor Receptor 2 (HER2)}, url = {https://www.tanaffosjournal.ir/article_240983.html}, eprint = {https://www.tanaffosjournal.ir/article_240983_199cd6e215f885b4c18268b20870eda8.pdf} }